Clinical trials: E Coli Infections
Antibiotic Resistance, Enterobacteriaceae Infections
Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France
Carbapenemase-producing Enterobacteriaceae (CPE) are classified as emerging Highly Resistant Bacteria (eHRB) because they expose infected patients to the risk of treatment failure due to the strains' resistance to last-line…
- Conditions
- Antibiotic Resistance, Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection, Colonization
- Trial name
- CARBACOLI (NCT07676513)
- Testing
- MultiLocus Sequence Typing
- Where
- France
- Volunteers
- 163 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Enterotoxigenic Escherichia Coli Infection, Diarrhea
Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701
This is a single-center, double-blind, placebo-controlled, Phase II vaccination and challenge study designed to confirm a human challenge model with E. coli strain LSN03-016011/A.
- Trial name
- NCT03576183
- Testing
- VLA1701, Challenge Strain
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Escherichia Coli Bloodstream Infection
Prognostic Factors of Escherichia Coli Bloodstream Infections: Severity Score and Therapeutic Implications
The determinants associated with severe outcome and death from Escherichia coli bloodstream infections (BSI) remain poorly understood. The epidemiology of E.
- Trial name
- SEPTICOLI (NCT02890901)
- Where
- France
- Volunteers
- 553 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Escherichia Coli Infections, Klebsiella Infections
Study Evaluating Antibiotic Use in Reducing Vancomycin-Resistant Enterococci and ESBL Producing Escherichia Coli and Klebsiella Pneumoniae in Intensive Care
To determine whether the restriction of 3rd generation cephalosporins and carbapenems contribute to the reduction of intestinal colonization or infection with vancomycin-resistant enterococci (VRE) in a medical intensive care…
- Trial name
- NCT00167986
- Testing
- vancomycin-resistant enterococci and ESBL
- Where
- South Korea
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Healthy Volunteers
ShigETEC Vaccine Study in Bangladesh
The goal of this clinical trial is to test ShigETEC vaccine, a combination vaccine against Shigella and ETEC diarrhoea in Bangladeshi adults (aged 18-45 years) and paediatric participants of three different age groups (aged 2-5…
- Trial name
- NCT05987488
- Testing
- ShigETEC live, attenuated, oral vaccine
- Where
- Bangladesh
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Eveliqure Biotechnologies GmbH
Escherichia Coli Infections, Klebsiella Pneumonia
Colonization With Extended-Spectrum Beta-Lactamase (ESBL)-Producing Organisms
There has been a great increase in the incidence of infections caused by bacteria that are resistant to antibiotic agents. Many of these infections result in worse outcomes of patients and increased costs to the healthcare…
- Trial name
- NCT01324726
- Where
- Lebanon
- Volunteers
- 100 people
- Sponsor
- American University of Beirut Medical Center
Gastroenteritis Escherichia Coli, Immunisation
A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area
This is a trial to evaluate the safety and immunogenicity of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by oral, sublingual, or intradermal vaccination in approximately 135…
- Trial name
- NCT03548064
- Testing
- Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
- Where
- 2 sites in United States, Bangladesh
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis E
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Lot Consistency Trial)
This study is to evaluate lot-lot consistency of Recombinant Hepatitis E Vaccine (Escherichia Coli) Hecolin®.
- Trial name
- NCT03365921
- Testing
- Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Enterobacteriaceae Infections
Epidemiology of Community - Associated Extended-spectrum Beta-lactamases (ESBL) Producing Escherichia Coli
The purpose of this study is to review patients with E. coli infections at the University of Pittsburgh Medical Center (UPMC) from July 1, 2007 to June 30, 2010 to determine if these infections have arisen in the community rather…
- Trial name
- NCT00573235
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Pittsburgh
Shigella Sonnei Dysenteries
Safety, Immunogenicity and Efficacy Study of Inactivated Whole Cell Shigella Flexneri 2a Vaccine With and Without dmLT in Adults
This is a research study about an experimental (investigational) oral inactivated whole cell Shigella flexneri 2a killed vaccine (Sf2aWC) and an adjuvant called dmLT.
- Trial name
- NCT03038243
- Testing
- Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT), Shigella flexneri 2a whole cell (Sf2aWC) vaccine
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- PATH
Diarrhea
Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)
This study will evaluate the safety of a prototype Coli surface antigen 6 (CS6) subunit vaccine (CssBA) alone or in combination with Escherichia coli double mutant heat labile toxin (dmLT) given by intramuscular (IM) injection.
- Trial name
- NCT03404674
- Testing
- CssBA, dmLT
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- PATH
Hepatitis E
Clinical Trial of Recombinant Hepatitis E Vaccine
The primary purpose of this study is to determine whether the preventive hepatitis E are effective in the prevention of hepatitis E occurring at least 30 days after the administration of the third dose of vaccine.
- Trial name
- NCT01014845
- Testing
- hepatitis E vaccine, Hepatitis B vaccine
- Where
- China
- Volunteers
- 112,604 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Infections
E. Coli Nissle 1917 - Suspension for Infection Prophylaxis
This study evaluates the long term effects of E. coli strain Nissle 1917 (EcN-Suspension) probiotic bacteria administration on the number of both, bacterial and viral infections during the first 24 months of infant's life.
- Trial name
- RONi (NCT02802059)
- Testing
- EcN-Suspension
- Where
- 6 sites in Germany, Poland
- Volunteers
- 567 people, healthy volunteers welcome
- Sponsor
- Ardeypharm GmbH
Dysentery
Identification of Correlates of Protection Against Shigella and Enterotoxigenic Escherichia Coli Infections
The aim of this study is to accelerate the development of vaccine candidates against diarrheal diseases caused by Shigella and Enterotoxigenic Escherichia coli (ETEC).
- Trial name
- NCT01638039
- Testing
- Laboratory Tests
- Where
- 7 sites in Israel
- Volunteers
- 330 people, healthy volunteers welcome
- Sponsor
- Hillel Yaffe Medical Center
Bloodstream Infections
RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.
No randomized controlled trials (RCTs) have yet been performed comparing different treatment options for AmpC or ESBL-producing Enterobacteriaceae.
- Trial name
- MERINO (NCT02176122)
- Testing
- Meropenem, Piperacillin-tazobactam combination product
- Where
- 31 sites in Australia, Canada and 7 more
- Volunteers
- 391 people
- Sponsor
- The University of Queensland
Escherichia Coli Infections
Effects of Nutritional Fat on the Growth of Intestinal E. Coli
Recent experiments in the lab of Prof. WD Hardt revealed, that in mice, 24 h exposure to a high-fat diet results in a breakdown of colonization resistance against Salmonella typhimurium.
- Trial name
- NCT03800147
- Testing
- "Mutaflor Suspension" (E. coli Nissle 1917), Blood samples, Stool samples
- Where
- Switzerland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Zurich
Hepatitis E
A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )
This phase IV clinical study was designed to evaluate the immunogenicity and safety of Hecolin® in the chronic Hepatitis B patients on the clinical stability.
- Trial name
- NCT02964910
- Testing
- Recombinant Hepatitis E Vaccine (Escherichia Coli)
- Where
- China
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Xiamen Innovax Biotech Co., Ltd
Urinary Tract Infections
Selective Reporting for Antibiotic Susceptibility Testing and GPs' Prescribing of Broad-spectrum Antibiotics in Women With E. Coli UTIs
The control of antibiotic resistance requires a reduction in inappropriate prescriptions of broad-spectrum antibiotics (amoxillin-clavulanate (AMC), fluoroquinolones (FQ), third-generation cephalosporins (C3G)), particularly for…
- Trial name
- ABC-MG (NCT06067386)
- Testing
- Dissemination of a selective reporting for antibiotic susceptibility testing, Standard antibiotic susceptibility testing report
- Where
- France
- Volunteers
- 3,000 people
- Sponsor
- Nantes University Hospital
Bacterial Infection, Diarrhea
Milk Ingredients and Resistance Against E-coli-induced GastroEnteritis (MIRAGE)
Background: The incidence of gastrointestinal infections is very high. In Western countries at least 30% of the population suffers from at least one food-borne infection per year.
- Conditions
- Bacterial Infection, Diarrhea, Gastroenteritis
- Trial name
- MIRAGE (NCT01800396)
- Testing
- Milk protein, Milk protein rich in phospholipids
- Where
- Netherlands
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- NIZO Food Research
Urinary Tract Infections
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation…
- Trial name
- NCT06702449
- Testing
- Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1
- Where
- 8 sites in United States, South Africa
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline